Next 10 |
home / stock / rnugf / rnugf news
2023-05-25 08:25:10 ET ReNeuron Group plc (RNUGF) Q1 2023 Earnings Conference Call May 25, 2023 04:30 AM ET Company Participants Iain Ross - Executive Chairman John Hawkins - CFO Randolph Corteling - Chief Scientific Officer Conference Call Participants ...
(NewsDirect) ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors to pr...
LONDON, UK / ACCESSWIRE / October 10, 2022 / ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-...
ReNeuron Group plc (RNUGF) Q4 2022 Results Conference Call July 4, 2022 10:00 AM ET Company Participants Iain Ross - Chairman Catherine Isted - CFO Randolph Corteling - Head of Research Presentation Operator Good afternoon, and welcome to the ...
ReNeuron Group plc. (RNUGF) Q2 2021 Results Earnings Conference Call November 30, 2021, 10:00 AM ET Company Participants Olav Hellebø - CEO Catherine Isted - CFO Stefano Pluchino - CSO Conference Call Participants Presentation Operator [Abrupt start] the ReNeuron Group plc Interim Result...
LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. T...
The following slide deck was published by ReNeuron Group plc in conjunction with their 2021 Q4 earnings call. For further details see: ReNeuron Group plc 2021 Q4 - Results - Earnings Call Presentation
ReNeuron Group plc (RNUGF) Q4 2021 Earnings Conference Call July 8, 2021, 11:30 AM ET Company Participants Olav Hellebø - Chief Executive Officer Dr. Richard Beckman - Chief Medical Officer John Hawkins - Financial Controller Shaun Stapleton - Vice President, Regulatory Affairs Conferenc...
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
ReNeuron Group ([[RNUGF]]) announces that it has completed dosing of the first cohort of three subjects in the Phase 2a extension segment of the study testing its hRPC (human retinal progenitor cell) therapy in patients with inherited blindness-causing disorder retinitis pigmentosa ((RP)).Thi...
News, Short Squeeze, Breakout and More Instantly...
ReNeuron Group Company Name:
RNUGF Stock Symbol:
OTCMKTS Market:
(NewsDirect) ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors to pr...
LONDON, UK / ACCESSWIRE / October 10, 2022 / ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-...
LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. T...